Chemotherapy regimens and treatment protocols for laryngeal cancer

Expert Opinion on Pharmacotherapy

Volumn 11, Issue 8, 2010, Pages 1305-1316

  Haigentz Jr , Missak ^a   Silver, Carl E ^a   Hartl, Dana M ^b,c   Takes, Robert P ^d   Rodrigo, Juan P ^e,f   Robbins, K Thomas ^g   Rinaldo, Alessandra ^h   Ferlito, Alfio ^h  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b INSTITUT GUSTAVE ROUSSY   (France)

^c Laboratoire de Phonetique et de Phonologie   (France)

^d RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^e HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

^f UNIVERSITY OF OVIEDO   (Spain)

^g SOUTHERN ILLINOIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h UNIVERSITY HOSPITAL OF UDINE   (Italy)

Author keywords

Cancer; Chemoradiotherapy; Chemotherapy; Laryngeal cancer; Larynx; Molecular targeted therapy; Treatment

Indexed keywords

ANTINEOPLASTIC AGENT; BLEOMYCIN; CARBOPLATIN; CETUXIMAB; CISPLATIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; FLUOROURACIL; METHOTREXATE; SODIUM THIOSULFATE;

ACNE; ADVANCED CANCER; ANTIANGIOGENIC ACTIVITY; AREA UNDER THE CURVE; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER EPIDEMIOLOGY; CANCER PREVENTION; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CANCER THERAPY; CATHETERIZATION; CELL CYCLE; CLINICAL ASSESSMENT; CLINICAL DECISION MAKING; CLINICAL STUDY; CONTINUOUS INFUSION; CYTOTOXICITY; DISTANT METASTASIS; DNA REPAIR; DOWN REGULATION; DRUG DETOXIFICATION; DRUG HYPERSENSITIVITY; DRUG TARGETING; DRUG TOLERABILITY; EAR NOSE THROAT SURGERY; EVENT FREE SURVIVAL; FEASIBILITY STUDY; FOLLOW UP; HEAD AND NECK CANCER; HIGH RISK PATIENT; HUMAN; HYPOPHARYNX CANCER; HYPOTHESIS; LARYNGECTOMY; LARYNGOSCOPY; LARYNX CANCER; LIGAND BINDING; LOADING DRUG DOSE; MOUTH CANCER; MUCOSA INFLAMMATION; MULTIMODALITY CANCER THERAPY; ORGAN PRESERVATION; OROPHARYNX CANCER; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PALLIATIVE THERAPY; POSTOPERATIVE CARE; PREOPERATIVE TREATMENT; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; RADIOSENSITIZATION; RETROSPECTIVE STUDY; REVIEW; RISK BENEFIT ANALYSIS; RISK FACTOR; ROBOTICS; SALVAGE THERAPY; SQUAMOUS CELL CARCINOMA; SURGICAL TECHNIQUE; SURVIVAL RATE; TREATMENT DURATION; TREATMENT RESPONSE; TUMOR BIOPSY; TUMOR BLOOD FLOW; TUMOR CELL; TUMOR VOLUME; VOICE;

ADENOCARCINOMA; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMBINED MODALITY THERAPY; HUMANS; INTERDISCIPLINARY COMMUNICATION; LARYNGEAL NEOPLASMS; MEDICAL ONCOLOGY; PATHOLOGY, MOLECULAR; RADIOTHERAPY, ADJUVANT; TREATMENT OUTCOME;

EID: 77952118528     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656561003749256     Document Type: Review

References (80)

1. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-216
2. Tarpley JL, Chretien PB, Alexander JC Jr, et al. High dose methotrexate as a preoperative adjuvant in the treatment of epidermoid carcinoma of the head and neck. A feasibility study and clinical trial. Am J Surg 1975;130:481-486
3. Kun LE, Toohill RJ, Holoye PY, et al. A randomized study of adjuvant chemotherapy for cancer of the upper aerodigestive tract. Int J Radiat Oncol Biol Phys 1986;12:173-178
4. Adjuvant chemotherapy for advanced head and neck squamous carcinoma. Final report of the Head and Neck Contracts Program. Cancer 1987;60:301-311
5. Toohill RJ, Duncavage JA, Grossmam TW, et al. The effects of delay in standard treatment due to induction chemotherapy in two randomized prospective studies. Laryngoscope 1987;97:407-412
6. Schuller DE, Metch B, Stein DW, et al. Preoperative chemotherapy in advanced resectable head and neck cancer: final report of the Southwest Oncology Group. Laryngoscope 1988;98:1205-1211
7. Gehanno P, Depondt J, Peynegre R, et al. Neoadjuvant combination of carboplatin and 5-FU in head and neck cancer: a randomized study. Ann Oncol 1992;3(Suppl 3):43-46
8. Jaulerry C, Rodriguez J, Brunin F, et al. Induction chemotherapy in advanced head and neck tumors: results of two randomized trials. Int J Radiat Oncol Biol Phys 1992;23:483-489
9. Mazeron JJ, Martin M, Brun B, et al. Induction chemotherapy in head and neck cancer: results of a phase III trial. Head Neck 1992;14:85-91
10. Paccagnella A, Orlando A, Marchiori C, et al. Phase III trial of initial chemotherapy in stage III or IV head and neck cancers: a study by the Gruppo di Studio sui Tumori della Testa e del Collo. J Natl Cancer Inst 1994;86:265-272
11. Al-Sarraf M. Chemotherapeutic management of head and neck cancer. Cancer Metastasis Rev 1987;6:181-198
12. Ensley JF, Jacobs JR, Weaver A, et al. Correlation between response to cisplatinum-combination chemotherapy and subsequent radiotherapy in previously untreated patients with advanced squamous cell cancers of the head and neck. Cancer 1984;54:811-814
13. Glick JH, Marcial V, Richter M, Velez-Garcia E. The adjuvant treatment of inoperable stage III and IV epidermoid carcinoma of the head and neck with platinum and bleomycin infusions prior to definitive radiotherapy: an RTOG pilot study. Cancer 1980;46:1919-1924
14. Hong WK, Bromer RH, Amato DA, et al. Patterns of relapse in locally advanced head and neck cancer patients who achieved complete remission after combined modality therapy. Cancer 1985;56:1242-1245
15. Jacobs C, Goffinet DR, Goffinet L, et al. Chemotherapy as a substitute for surgery in the treatment advanced resectable head and neck cancer. A report from the Northern California Oncology Group. Cancer 1987;60:1178-1183
16. Karp DD, Vaughan CW, Carter R, et al. Larynx preservation using induction chemotherapy plus radiation therapy as an alternative to laryngectomy in advanced head and neck cancer. A longterm follow-up report. Am J Clin Oncol 1991;14:273-279
17. The Department of Veterans Affairs Laryngeal Cancer Study Group. Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer. N Engl J Med 1991;324:1685-1690
18. Hillman RE, Walsh MJ, Wolf GT, et al. Functional outcomes following treatment for advanced laryngeal cancer. Part I--Voice preservation in advanced laryngeal cancer. Part II--Laryngectomy rehabilitation: the state of the art in the VA System. Research Speech-Language Pathologists. Department of Veterans Affairs Laryngeal Cancer Study Group. Ann Otol Rhinol Laryngol Suppl 1998;172:1-27
19. Lefebvre JL, Chevalier D, Luboinski B, et al. Larynx preservation in pyriform sinus cancer: preliminary results of a European Organization for Research and Treatment of Cancer phase III trial. EORTC Head and Neck Cancer Cooperative Group. J Natl Cancer Inst 1996;88:890-899
20. Richard JM, Sancho-Garnier H, Pessey JJ, et al. Randomized trial of induction chemotherapy in larynx carcinoma. Oral Oncol 1998;34:224-228
21. Pignon JP, Bourhis J, Domenge C, Designe L. Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. MACH-NC Collaborative Group. Meta-analysis of chemotherapy on head and neck cancer. Lancet 2000;355:949-955
22. Pointreau Y, Garaud P, Chapet S, et al. Randomized trial of induction chemotherapy with cisplatin and 5-fluorouracil with or without docetaxel for larynx preservation. J Natl Cancer Inst 2009;101:498-506
23. Bourhis J, Wilson G, Wibault P, et al. Rapid tumor cell proliferation after induction chemotherapy in oropharyngeal cancer. Laryngoscope 1994;104:468-472
24. Duncan W, MacDougall RH, Kerr GR, Downing D. Adverse effect of treatment gaps in the outcome of radiotherapy for laryngeal cancer. Radiother Oncol 1996;41:203-207
25. Peters LJ, Withers HR. Applying radiobiological principles to combined modality treatment of head and neck cancer--the time factor. Int J Radiat Oncol Biol Phys 1997;39:831-836
26. Withers HR, Maciejewski B, Taylor JM, Hliniak A. Accelerated repopulation in head and neck cancer. Front Radiat Ther Oncol 1988;22:105-110
27. Adelstein DJ, Sharan VM, Earle AS, et al. Simultaneous versus sequential combined technique therapy for squamous cell head and neck cancer. Cancer 1990;65:1685-1691
28. Merlano M, Benasso M, Corvo R, et al. Five-year update of a randomized trial of alternating radiotherapy and chemotherapy compared with radiotherapy alone in treatment of unresectable squamous cell carcinoma of the head and neck. J Natl Cancer Inst 1996;88:583-589
29. Al-Sarraf M, LeBlanc M, Giri PG, et al. Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099. J Clin Oncol 1998;16:1310-1317
30. Wendt TG, Grabenbauer GG, Rodel CM, et al. Simultaneous radiochemotherapy versus radiotherapy alone in advanced head and neck cancer: a randomized multicenter study. J Clin Oncol 1998;16:1318-1324
31. Calais G, Alfonsi M, Bardet E, et al. Randomized trial of radiation therapy versus concomitant chemotherapy and radiation therapy for advanced-stage oropharynx carcinoma. J Natl Cancer Inst 1999;91:2081-2086
32. Forastiere AA, Goepfert H, Maor M, et al. Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med 2003;349:2091-2098
33. Goepfert H, Jesse RH, Fletcher GH, Hamberger A. Optimal treatment for the technically resectable squamous cell carcinoma of the supraglottic larynx. Laryngoscope 1975;85:14-32
34. Harwood AR, Hawkins NV, Beale FA, et al. Management of advanced glottic cancer. A 10 year review of the Toronto experience. Int J Radiat Oncol Biol Phys 1979;5:899-904
35. Harwood AR, Bryce DP, Rider WD. Management of T3 glottic cancer. Arch Otolaryngol 1980;106:697-699
36. Harwood AR, Beale FA, Cummings BJ, et al. Supraglottic laryngeal carcinoma: an analysis of dose-time-volume factors in 410 patients. Int J Radiat Oncol Biol Phys 1983;9:311-319
37. Croll GA, Gerritsen GJ, Tiwari RM, Snow GB. Primary radiotherapy with surgery in reserve for advanced laryngeal carcinoma. Results and complications. Eur J Surg Oncol 1989;15:350-356
38. Forastiere AA, Maor M, Weber RS, et al. Long-term results of Intergroup RTOG 91-11: a phase III trial to preserve the larynx--Induction cisplatin/5-FU and radiation therapy versus concurrent cisplatin and radiation therapy versus radiation therapy [abstract]. 2006 ASCO Annual Meeting Proceedings Part I. J Clin Oncol 2006;24:5517
39. Lefebvre JL, Rolland F, Tesselaar M, et al. Phase 3 randomized trial on larynx preservation comparing sequential vs alternating chemotherapy and radiotherapy. J Natl Cancer Inst 2009;101:142-152
40. Pignon JP, le Maitre A, Maillard E, Bourhis J. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients. Radiother Oncol 2009;92:4-14
41. Vokes EE, Kies M, Haraf DJ, et al. Induction chemotherapy followed by concomitant chemoradiotherapy for advanced head and neck cancer: impact on the natural history of the disease. J Clin Oncol 1995;13:876-883
42. Kies MS, Haraf DJ, Athanasiadis I, et al. Induction chemotherapy followed by concurrent chemoradiation for advanced. head and neck cancer: improved disease control and survival. J Clin Oncol 1998;16:2715-2721
43. Mantz CA, Vokes EE, Kies MS, et al. Sequential induction chemotherapy and concomitant chemoradiotherapy in the management of locoregionally advanced laryngeal cancer. Ann Oncol 2001;12:343-347
44. Machtay M, Rosenthal DI, Hershock D, et al. Organ preservation therapy using induction plus concurrent chemoradiation for advanced resectable oropharyngeal carcinoma: a University of Pennsylvania Phase II Trial. J Clin Oncol 2002;20:3964-3971
45. Guadagnolo BA, Haddad RI, Posner MR, et al. Organ preservation and treatment toxicity with induction chemotherapy followed by radiation therapy or chemoradiation for advanced laryngeal cancer. Am J Clin Oncol 2005;28:371-378
46. Hitt R, Lopez-Pousa A, Martinez-Trufero J, et al. Phase III study comparing cisplatin plus fluorouracil to paclitaxel, cisplatin, and fluorouracil induction chemotherapy followed by chemoradiotherapy in locally advanced head and neck cancer. J Clin Oncol 2005;23:8636-8645
47. Posner MR, Hershock DM, Blajman CR, et al. Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N Engl J Med 2007;357:1705-1715
48. Posner MR, Norris CM, Wirth LJ, et al. Sequential therapy for the locally advanced larynx and hypopharynx cancer subgroup in TAX 324: survival, surgery, and organ preservation. Ann Oncol 2009;20:921-927
49. Huang SM, Bock JM, Harari PM. Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck. Cancer Res 1999;59:1935-1940
50. Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 2006;354:567-578
51. Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol 2010;11:21-28
52. Curran D, Giralt J, Harari PM, et al. Quality of life in head and neck cancer patients after treatment with high-dose radiotherapy alone or in combination with cetuximab. J Clin Oncol 2007;25:2191-2197
53. Forastiere AA, Takasugi BJ, Baker SR, et al. High-dose cisplatin in advanced head and neck cancer. Cancer Chemother Pharmacol 1987;19:155-158
54. Forastiere AA, Baker SR, Wheeler R, Medvec BR. Intra-arterial cisplatin and FUDR in advanced malignancies confined to the head and neck. J Clin Oncol 1987;5:1601-1606
55. Mortimer JE, Taylor ME, Schulman S, et al. Feasibility and efficacy of weekly intraarterial cisplatin in locally advanced (stage III and IV) head and neck cancers. J Clin Oncol 1988;6:969-975
56. Robbins KT, Kumar P, Regine WF, et al. Efficacy of targeted supradose cisplatin and concomitant radiation therapy for advanced head and neck cancer: the Memphis experience. Int J Radiat Oncol Biol Phys 1997;38:263-271
57. Robbins KT, Fontanesi J, Wong FS, et al. A novel organ preservation protocol for advanced carcinoma of the larynx and pharynx. Arch Otolaryngol Head Neck Surg 1996;122:853-857
58. Samant S, Kumar P, Wan J, et al. Concomitant radiation therapy and targeted cisplatin chemotherapy for the treatment of advanced pyriform sinus carcinoma: disease control and preservation of organ function. Head Neck 1999;21:595-601
59. Samant S, Robbins KT, Kumar P, et al. Bone or cartilage invasion by advanced head and neck cancer: intra-arterial supradose cisplatin chemotherapy and concomitant radiotherapy for organ preservation. Arch Otolaryngol Head Neck Surg 2001;127:1451-1456
60. Robbins KT, Kumar P, Harris J, et al. Supradose intra-arterial cisplatin and concurrent radiation therapy for the treatment of stage IV head and neck squamous cell carcinoma is feasible and efficacious in a multi-institutional setting: results of Radiation Therapy Oncology Group Trial 9615. J Clin Oncol 2005;23:1447-1454
61. Staton J, Robbins KT, Newman L, et al. Factors predictive of poor functional outcome after chemoradiation for advanced laryngeal cancer. Otolaryngol Head Neck Surg 2002;127:43-47
62. Urba S, Wolf G, Eisbruch A, et al. Single-cycle induction chemotherapy selects patients with advanced laryngeal cancer for combined chemoradiation: a new treatment paradigm. J Clin Oncol 2006;24:593-598
63. Worden FP, Moyer J, Lee JS, et al. Chemoselection as a strategy for organ preservation in patients with T4 laryngeal squamous cell carcinoma with cartilage invasion. Laryngoscope 2009;119:1510-1517
64. Brizel DM, Albers ME, Fisher SR, et al. Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer. N Engl J Med 1998;338:1798-1804
65. Chen C, Kane M, Song J, et al. Phase I trial of gefitinib in combination with radiation or chemoradiation for patients with locally advanced squamous cell head and neck cancer. J Clin Oncol 2007;25:4880-4886
66. Bernier J, Domenge C, Ozsahin M, et al. Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med 2004;350:1945-1952 (Pubitemid 38580197)
67. Cooper JS, Pajak TF, Forastiere AA, et al. Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. N Engl J Med 2004;350:1937-1944
68. Bradford CR, Wolf GT, Carey TE, et al. Predictive markers for response to chemotherapy, organ preservation, and survival in patients with advanced laryngeal carcinoma. Otolaryngol Head Neck Surg 1999;121:534-538
69. Laccourreye O, Brasnu D, Bassot V, et al. Cisplatin-fluorouracil exclusive chemotherapy for T1-T3N0 glottic squamous cell carcinoma complete clinical responders: five-year results. J Clin Oncol 1996;14:2331-2336
70. Laccourreye O, Veivers D, Bassot V, et al. Analysis of local recurrence in patients with selected T1-3N0M0 squamous cell carcinoma of the true vocal cord managed with a platinum-based chemotherapy-alone regimen for cure. Ann Otol Rhinol Laryngol 2002;111:315-21; discussion 21-22
71. Bonfils P, Trotoux J, Bassot V. Chemotherapy alone in laryngeal squamous cell carcinoma. J Laryngol Otol 2007;121:143-148
72. Holsinger FC, Kies MS, Diaz EM Jr, et al. Durable long-term remission with chemotherapy alone for stage II to IV laryngeal cancer. J Clin Oncol 2009;27:1976-1982
73. Holsinger FC, Lin HY, Bassot V, Laccourreye O. Platin-based exclusive chemotherapy for selected patients with squamous cell carcinoma of the larynx and pharynx. Cancer 2009;115:3909-3918
74. Haigentz M Jr, Silver CE, Rinaldo A, Ferlito A. Definitive chemotherapy: a new frontier in the fight against laryngeal cancer [editorial]. Eur Arch Otorhinolaryngol 2010;267:1-4
75. Strojan P, Ferlito A, Wu CF, Rinaldo A. Intraarterial chemotherapy: a valid option in the treatment of verrucous carcinoma? Eur Arch Otorhinolaryngol 2009: published online 27 December 2009, doi: 10.1007/s00405-009-1178-2
76. Divi V, Worden FP, Prince ME, et al. Chemotherapy alone for organ preservation in advanced laryngeal cancer. Head Neck 2009: published online 1 December 2009, doi: 10.1002/hed.21285
77. Hartl DM, Brasnu DF. Chemotherapy alone for glottic carcinoma: a need for higher-level evidence. Ann Otol Rhinol Laryngol 2009;118:543-545
78. Vermorken JB, Trigo J, Hitt R, et al. Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy. J Clin Oncol 2007;25:2171-2177
79. Vermorken JB, Mesia R, Rivera F, et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 2008;359:1116-1127
80. Silver CE, Beitler JJ, Shaha AR, et al. Current trends in initial management of laryngeal cancer: the declining use of open surgery. Eur Arch Otorhinolaryngol 2009;266:1333-1352